Senate bill targets drug patent abuses—but could it backfire on innovation?

The Senate HELP Committee will vote on 17 June on a set of bills designed to lower medical costs. One of these, the Medication Affordability and Patent Integrity Act, introduces new disclosure and certification rules for drug companies. Its aim is to stop firms from exploiting the patent system to secure undeserved protections. The bill requires pharmaceutical companies to share more data with both the FDA and the USPTO. Its supporters argue this will ensure both agencies have the same information, preventing firms from withholding key details from patent examiners. However, the two agencies serve different purposes, and it remains unclear whether aligning their data will improve patent reviews.

Critics point out that patent applicants already follow strict disclosure and good faith rules. They also highlight that extra paperwork will increase compliance work, legal reviews, and potential litigation. This could divert resources away from research and development.

The proposal also raises confidentiality issues. FDA submissions often include sensitive, proprietary information. Unlike patent filings, these details currently receive no protection under patent law.

There is no evidence that current safeguards have failed to prevent companies from withholding material information. Additionally, some warn the bill could make the patent system less predictable. This uncertainty might discourage medical innovation and weaken global competitiveness. The bill seeks to prevent drug companies from manipulating patent protections. Yet its potential to increase administrative burdens and reduce patent security has drawn strong concerns. The Senate HELP Committee will decide its fate in the upcoming vote.